PROCEPT BioRobotics (PRCT)

Overall impact
B (64)

Commentary

PROCEPT BioRobotics is a strong overall performer. With a 'B' rating of 63.6 for overall impact (70th percentile compared to all companies), PROCEPT BioRobotics ranks 94th out of 155 industry peers, behind American Shared Hospital Services, Accuray, Avinger and 90 others, and ahead of Hologic, Adm Tronics Unlimited, Top Glove Corporation and 58 others. On top material causes for PROCEPT BioRobotics's industry (Healthcare Equipment), PROCEPT BioRobotics performs well in Disease Eradication (95.7 score), Child and Maternal Health (95.9), Access to Affordable Healthcare (95.9) and 2 other causes where it received an 'A' score and performs poorly in Decent, Safe Work Opportunities (33.1 score), Accountable Institutions (31.1), Humane Treatment of Animals (22.3) and 4 other causes where it received a 'D' or 'F' score.
Impact
Cause PRCT
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2007
Employees
428
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Health Care Delivery
Headquarters
California, United States
Share classes
PRCT
Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Material causes
Ethos considers the following causes material for PROCEPT BioRobotics, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.